Literature DB >> 17096325

Inflammation and IGF-I activate the Akt pathway in breast cancer.

Robyn L Prueitt1, Brenda J Boersma, Tiffany M Howe, Julie E Goodman, Douglas D Thomas, Lei Ying, Candice M Pfiester, Harris G Yfantis, John R Cottrell, Dong H Lee, Alan T Remaley, Lorne J Hofseth, David A Wink, Stefan Ambs.   

Abstract

Akt signaling may promote breast cancer progression and poor disease outcome. We hypothesized that serum insulin-like growth factor I (IGF-I) and a proinflammatory tumor environment induce phosphorylation of Akt and downstream targets of Akt in breast cancer. We studied the relationship between Akt pathway activation, IGF-I and markers of inflammation, e.g., nitric oxide synthase-2 (NOS2), cyclooxygenase-2 (COX2) and tumor phagocyte density, in 248 breast tumors. We also examined the association of Akt phosphorylation with breast cancer survival. We observed that phosphorylation of Akt, BAD and caspase-9 correlated strongly with the expression of the 2 proinflammatory enzymes, NOS2 and COX2, in breast tumors (p < 0.001; Spearman rank correlation). Both NOS2 and COX2 expression were independently associated with Akt phosphorylation in the multivariate analysis. Serum IGF-I concentrations and the IGF-I/IGFBP3 ratio correlated with Akt phosphorylation at Thr308 and Ser473 in breast tumors (p <or= 0.05; Spearman rank correlation). The association with Akt phosphorylation at Thr308 remained statistically significant in the multivariate analysis. Akt pathway activation was not associated with overall survival in the unstratified analysis, but we observed a statistical interaction between Akt phosphorylation and tumor phagocyte density on breast cancer survival (p(interaction) < 0.05). We further corroborated our findings in cell culture models by demonstrating that ANA-1 macrophages, nitric oxide and prostaglandin E(2) induce Akt phosphorylation in human breast cancer cells. In summary, a proinflammatory environment was found to activate the Akt pathway in breast cancer, and may modify the association between the Akt phosphorylation status and breast cancer survival.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17096325     DOI: 10.1002/ijc.22336

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  45 in total

1.  Expression of Human Endogenous Retrovirus Type K Envelope Protein is a Novel Candidate Prognostic Marker for Human Breast Cancer.

Authors:  Jing Zhao; Kiera Rycaj; Shanshan Geng; Ming Li; Joshua B Plummer; Bingnan Yin; Hong Liu; Xu Xu; Yinchun Zhang; Yanfang Yan; Sharon A Glynn; Tiffany H Dorsey; Stefan Ambs; Gary L Johanning; Lin Gu; Feng Wang-Johanning
Journal:  Genes Cancer       Date:  2011-09

2.  Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients.

Authors:  Sharon A Glynn; Brenda J Boersma; Tiffany H Dorsey; Ming Yi; Harris G Yfantis; Lisa A Ridnour; Damali N Martin; Christopher H Switzer; Robert S Hudson; David A Wink; Dong H Lee; Robert M Stephens; Stefan Ambs
Journal:  J Clin Invest       Date:  2010-10-18       Impact factor: 14.808

3.  NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression.

Authors:  Hirokazu Okayama; Motonobu Saito; Naohide Oue; Jonathan M Weiss; Jimmy Stauffer; Seiichi Takenoshita; Robert H Wiltrout; S Perwez Hussain; Curtis C Harris
Journal:  Int J Cancer       Date:  2012-06-13       Impact factor: 7.396

4.  Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA.

Authors:  Mark Mackiewicz; Konrad Huppi; Jason J Pitt; Tiffany H Dorsey; Stefan Ambs; Natasha J Caplen
Journal:  Breast Cancer Res Treat       Date:  2011-08-04       Impact factor: 4.872

Review 5.  Nitric oxide release: part III. Measurement and reporting.

Authors:  Peter N Coneski; Mark H Schoenfisch
Journal:  Chem Soc Rev       Date:  2012-02-24       Impact factor: 54.564

6.  Liver- and Microbiome-derived Bile Acids Accumulate in Human Breast Tumors and Inhibit Growth and Improve Patient Survival.

Authors:  Wei Tang; Vasanta Putluri; Chandrashekar R Ambati; Tiffany H Dorsey; Nagireddy Putluri; Stefan Ambs
Journal:  Clin Cancer Res       Date:  2019-07-11       Impact factor: 12.531

7.  ADHFE1 is a breast cancer oncogene and induces metabolic reprogramming.

Authors:  Prachi Mishra; Wei Tang; Vasanta Putluri; Tiffany H Dorsey; Feng Jin; Fang Wang; Donewei Zhu; Lauren Amable; Tao Deng; Shaofei Zhang; J Keith Killian; Yonghong Wang; Tsion Z Minas; Harry G Yfantis; Dong H Lee; Arun Sreekumar; Michael Bustin; Wei Liu; Nagireddy Putluri; Stefan Ambs
Journal:  J Clin Invest       Date:  2017-11-27       Impact factor: 14.808

8.  Immunotherapeutic potential of anti-human endogenous retrovirus-K envelope protein antibodies in targeting breast tumors.

Authors:  Feng Wang-Johanning; Kiera Rycaj; Joshua B Plummer; Ming Li; Bingnan Yin; Katherine Frerich; Jeremy G Garza; Jianjun Shen; Kevin Lin; Peisha Yan; Sharon A Glynn; Tiffany H Dorsey; Kelly K Hunt; Stefan Ambs; Gary L Johanning
Journal:  J Natl Cancer Inst       Date:  2012-01-12       Impact factor: 13.506

Review 9.  Nitric Oxide Synthase-2-Derived Nitric Oxide Drives Multiple Pathways of Breast Cancer Progression.

Authors:  Debashree Basudhar; Veena Somasundaram; Graciele Almeida de Oliveira; Aparna Kesarwala; Julie L Heinecke; Robert Y Cheng; Sharon A Glynn; Stefan Ambs; David A Wink; Lisa A Ridnour
Journal:  Antioxid Redox Signal       Date:  2016-09-07       Impact factor: 8.401

10.  Mechano-transduction in osteoblastic cells involves strain-regulated estrogen receptor alpha-mediated control of insulin-like growth factor (IGF) I receptor sensitivity to Ambient IGF, leading to phosphatidylinositol 3-kinase/AKT-dependent Wnt/LRP5 receptor-independent activation of beta-catenin signaling.

Authors:  Andrew Sunters; Victoria J Armstrong; Gul Zaman; Robert M Kypta; Yoshiaki Kawano; Lance E Lanyon; Joanna S Price
Journal:  J Biol Chem       Date:  2009-12-30       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.